LEADER 01527oam  2200433Ia 450 
001 9910698771603321
005 20090406142301.0
035   $a(CKB)5470000002396139
035   $a(OCoLC)317883427
035   $a(OCoLC)995470000002396139
035   $a(EXLCZ)995470000002396139
100   $a20090406d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eS1C(R2) dose selection for carcinogenicity studies
210  1$aSilver Spring, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research ;$a[Rockville, MD] :$cCenter for Biologics Evaluation and Research,$d[2008]
215   $ai, 10 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on Apr. 6, 2009).
300   $a"ICH."
300   $a"Revision 1."
300   $a"September 2008."
517   $aGuidance for industry 
606   $aDrugs$xDosage
606   $aCarcinogenicity testing
615  0$aDrugs$xDosage.
615  0$aCarcinogenicity testing.
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
712 12$aInternational Conference on Harmonisation.
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910698771603321
996   $aGuidance for industry$93434577
997   $aUNINA